Custom Semaglutide CAS NO: 910463-68-2 - Leading China Suppliers and Factory for Effective Weight Management Solutions Quotes, Service
Product Description
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that have been clinically proven to be effective in helping individuals manage their weight. By mimicking the effects of the natural hormone GLP-1, semaglutide plays a vital role in regulating appetite and blood sugar levels. This innovative approach not only aids in weight loss, but also improves metabolic health, making it a comprehensive solution for those seeking to change their lifestyle.
Mechanism & Efficacy
Semaglutide is a GLP-1 receptor agonist that regulates blood glucose by stimulating insulin secretion and inhibiting glucagon release. It is commonly used in clinical research for type 2 diabetes management, weight management, and obesity-related studies.
Dosage & Clinical Use
Semaglutide (marketed as Wegovy®/Ozempic®) is administered by once‑weekly subcutaneous injection. Common dosing protocols for obesity and weight management range from 0.25 mg up to 2.4 mg weekly, with gradual titration based on tolerance and therapeutic goals. A new higher 7.2 mg weekly dose has been approved in some regions to enhance weight‑loss efficacy in clinical settings.
Patent & Intellectual Property
Semaglutide is protected by a broad patent portfolio covering compositions, formulations, and therapeutic uses. Key U.S. patents include:
- US11318191 – GLP‑1 compositions and uses, expires Feb 17, 2041
- US11478533 – Related formulation claim, expires May 13, 2040
- US12214017 / US8129343B2 – Additional composition/use patents, expiring 2038‑2041
These extended protections help delay generic competition in major markets such as the U.S. until the late 2030s–early 2040s.
Frequently Asked Questions
What is Semaglutide primarily used for?
Semaglutide is primarily used for type 2 diabetes management, weight management, and improving overall metabolic health by regulating appetite and blood sugar levels.
How does Semaglutide work in the body?
It acts as a GLP-1 receptor agonist, mimicking the natural GLP-1 hormone. This stimulates insulin secretion and inhibits glucagon release, which effectively regulates blood glucose and appetite.
How is Semaglutide administered?
Semaglutide is typically administered through a once-weekly subcutaneous injection.
What is the standard weekly dosage for weight management?
Common dosing protocols range from 0.25 mg up to 2.4 mg weekly, with gradual titration. In some regions, a higher 7.2 mg weekly dose has been approved for enhanced efficacy.
Under what brand names is Semaglutide marketed?
Semaglutide is commonly marketed under the brand names Wegovy® and Ozempic®.
When do the major patents for Semaglutide expire?
Key U.S. patents protecting Semaglutide are expected to expire between 2038 and 2041, which delays generic competition until the late 2030s or early 2040s.
